Proudman C, et al. - Via assessing data from the South Australian Health Omnibus Survey, researchers ascertained the prevalence of self-reported gout and gout flares, the use of urate-lowering therapy (ULT), and the association of gout flares with health-related quality of life (HRQoL). Further, they investigated covariate associations with flare frequency and allopurinol use. The analysis revealed a gout prevalence of 6.5%. Among participants with gout, 25% reported frequent flares (≥ 2 in the last year); younger age, higher body mass index, and current allopurinol use were noted to be correlated with frequent flares. Reduced physical HRQoL was reported among patients reporting gout flares. Allopurinol use was not reported in almost one-half of people with frequent gout flares, and frequent gout flares were evident in correlation to current allopurinol use. Findings suggested undertreated disease and suboptimal use of ULT.